Rheumatoid Arthritis Testing Market to Approach $400 million
In 2015, revenue from the rheumatoid arthritis (RA) testing market across the 15MM was $338.5m. Sales in the RA testing market are expected to undergo steady growth throughout the forecast period, reaching $399.5m in 2022, at a CAGR of 2.4%. The US and Japan currently contribute a significant portion of the RA testing diagnostics market, and will continue to do so through the end of the forecast period. Together, these two countries represented 43.7% of the total market revenue in 2015, with the US alone at 29.8%.
Key drivers of growth in this market during the forecast period include:
Increasing prevalence of autoimmune diseases globally, including RA
Emerging biomarkers and advancement in technology for the early diagnosis of RA
Increasing adoption of anti-cyclic citrullinated peptide (anti-CCP) antibody tests
Rising demand for lab automation
Key barriers to growth in this market during the forecast period include:
Limited sensitivity of existing RA diagnostic tests
Healthcare cost-cutting and reduced reimbursement in major markets
GlobalData’s latest MediPoint: Rheumatoid Arthritis Testing – Global Analysis and Market Forecasts, report provides:
Competitive assessment: Currently marketed RA diagnostic products and evolving competitive landscape
Pipeline analysis: Emerging products and technologies
In-depth analysis of unmet needs and adoption trends of different RA diagnostic tests
Insightful review of the key industry drivers, opportunities, restraints and challenges.
Annualized total RA testing market revenue by segment and market outlooks by country from 2013-2022.